Clinical trials: Antibody Mediated
Multiple Myeloma, Myeloma
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Background: Recent studies have shown that smoldering multiple myeloma has a high risk of progressing to multiple myeloma, an aggressive type of bone marrow cancer, within 5 years of diagnosis.
- Conditions
- Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT01248455
- Testing
- (Anti-KIR)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Transplantation
Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.
Chronic AntiBody-Mediated Rejection (cABMR) is the leading cause of late kidney transplant loss (after 1 year of kidney transplantation).
- Trial name
- IPECAM (NCT04870437)
- Testing
- Extracorporeal phototherapy
- Where
- 4 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Angers
Anti-NMDA Receptor Encephalitis
Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage
The encephalitis mediated by antibodies against the NMDA receptor (NMDARe) predominantly affects young adults and children resulting in severe neurologic and psychiatric deficits.
- Trial name
- AMENDS (NCT06183788)
- Testing
- Remote cognitive rehabilitation program
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Kidney Transplantation, Kidney Transplant Rejection
BAFF/APRIL in Kidney Transplant Rejection Risk Assessment
Antibody-mediated rejection (AMR) is a significant risk factor for graft loss in kidney transplantation. Soluble B cell-activating factor (sBAFF) and a proliferation-inducing ligand (APRIL) plays a critical role in the activation…
- Trial name
- BA-TRAP (NCT05779124)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced…
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor
- Trial name
- NCT03319459
- Testing
- FATE-NK100, Cetuximab, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fate Therapeutics
Biliary Tract Neoplasms, Liver Cancer
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response.
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT02821754
- Testing
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Neutrophil Extracellular Traps; Antiphospholipid Antibody-induced Pregnancy Loss
Neutrophil Extracellular Traps Mediate Antiphospholipid Antibody-induced Pregnancy Loss
1. Establish a multi-platform detection system for neutrophil extracellular traps in blood and tissues, and evaluate the detection performance; 2.
- Trial name
- NCT03735108
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shanghai First Maternity and Infant Hospital
Heart Block Complete, Heart Block Second Degree
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice.
- Trial name
- NCT04559425
- Testing
- Dexamethasone, No Dexamethasone
- Where
- 27 sites in United States, Bulgaria and 10 more
- Volunteers
- 350 people
- Sponsor
- The Hospital for Sick Children
Antibody-mediated Rejection, Kidney Transplant Rejection
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney transplant recipients (KTRs). Although it is a well characterized entity, there is limited data regarding effective treatment options for…
- Conditions
- Antibody-mediated Rejection, Kidney Transplant Rejection, Graft Loss
- Trial name
- NCT04367610
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Istanbul University
Myocardial Diseases, Parvovirus B19, Human
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
A prospective randomized double-blind placebo-controlled trail to investigate the effect of high doses of IVIg on cardiac functional capacity and virus presence in a subgroup of patients with chronic symptomatic ICM and a high…
- Trial name
- NCT00892112
- Testing
- Intravenous Immunoglobulins, plasma volume expander
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Prothya Biosolutions
Cow's Milk Allergy
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
Study to assess the diagnostic accuracy (sensitivity, specificity, positive and negative predictive value) of DBV1605 for the diagnosis of non-Immunoglobulin E (IgE) mediated cow's milk allergy (CMA) in children with symptoms…
- Trial name
- APTITUDE (NCT04492683)
- Testing
- DBV1605
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- DBV Technologies
Antibody-Mediated Rejection (AMR)
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure.
- Trial name
- NCT07613359
- Testing
- Mezagitamab
- Where
- 35 sites in United States, China and 3 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Kidney Transplant
Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
The purpose of this study is to try to determine if the drug eculizumab can help prevent antibody-mediated rejection in patients undergoing a kidney transplant from a living donor with a different blood type than their own.
- Trial name
- ABOi (NCT01095887)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Kidney Transplantation
Effect of Privigen Against Graft Loss
The principal objective of this pilot study is to determine whether the progression of chronic antibody-mediated rejection (ABMR) could be minimized by the post-transplant administration of high dose of Intravenous…
- Trial name
- InAuGuRAL (NCT02374736)
- Testing
- Privigen (Human normal immunoglobulin G (IgG > 98 % purity))
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody Mediated Rejection of Kidney Transplant
C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an…
- Trial name
- NCT02936479
- Testing
- C1-INH (Berinert)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health
Antibody Mediated Rejection After Kidney Transplantation
Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection
This clinical trial aims to determine whether a bispecific T-cell engager (BiTE) targeting BCMA×CD3 effectively treats chronic active antibody-mediated rejection (cAMR) in kidney transplant recipients.
- Trial name
- NCT07689578
- Testing
- BiTE (BCMA x CD3 Bispecific Antibody)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Turun Song
Antibody-mediated Rejection, Kidney Tranplant
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
Renal transplantation is the best choice for the treatment of end-stage renal disease, but the long-term survival of the graft is still remains a challenge.
- Trial name
- NCT05913596
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Purpura, Thrombotic Thrombocytopenic
IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
The main purpose of this study is to evaluate safety and tolerability in patients diagnosed with asymptomatic antibody-mediated TTP with low ADAMTS13 activity after receiving single intravenous dose of IdeS.
- Trial name
- NCT02854059
- Testing
- IdeS (0.25 mg/kg), IdeS (0.50 mg/kg)
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Hansa Biopharma AB
Ovarian Cancer
The Effect of TRA-8 on Ovarian Cancer Tissue
The goal of this study is to determine the apoptosis-inducing efficacy of TRA-8 in patient ovarian cancer tissues using a tissue slice technology.
- Trial name
- NCT00711932
- Where
- United States
- Volunteers
- 478 people
- Sponsor
- University of Alabama at Birmingham
Antibody-mediated Rejection
Felzartamab in Late Antibody-Mediated Rejection
This prospective trial will assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and efficacy of the fully human CD38 monoclonal antibody felzartamab in kidney transplant recipients with late active…
- Trial name
- NCT05021484
- Testing
- Felzartamab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 22 people
- Sponsor
- Farsad Eskandary